Parabilis Medicines, Inc.

Parabilis Medicines is an early-stage drug company developing new cancer treatments using a technology called helical peptides, which are small protein-based molecules. The company focuses on targeting proteins that have been hard to work with using traditional drug-making methods. Their main experimental drug, FOG-001, is designed to block a protein called beta-catenin that helps certain cancers grow. The company uses artificial intelligence to help discover and test new drugs faster.